Zafgen Owners | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Zafgen Inc.

Zafgen Inc. | Ownership

Companies that own Zafgen Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Great Point Partners LLC

3,500,000

9.51%

3,500,000

4.57%

06/30/2018

Fidelity Management & Research Co.

3,101,572

8.43%

-966,948

07/31/2018

683 Capital Management LLC

1,600,000

4.34%

300,000

1.74%

06/30/2018

Armistice Capital LLC

1,500,000

4.08%

600,000

1.09%

06/30/2018

BlackRock Fund Advisors

1,327,243

3.61%

959,194

06/30/2018

Farallon Capital Management LLC

1,266,539

3.44%

1,266,539

0.08%

06/30/2018

The Vanguard Group, Inc.

1,243,317

3.38%

333,500

06/30/2018

Invus Public Equities Advisors LLC

1,200,000

3.26%

0.38%

06/30/2018

Dimensional Fund Advisors LP

914,694

2.49%

49,722

06/30/2018

Mangrove Partners

737,629

150,000

1.09%

06/30/2018

About Zafgen

View Profile

Address	175 Portland Street Boston Massachusetts 02114 United States
Employees	-
Website	http://www.zafgen.com
Updated	07/08/2019
Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders. It offers the ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of type 2 diabetes. The company was founded on November 22, 2005 and is headquartered in Boston, MA.